When a company makes payments to directors, their family members, or related entities before insolvency, those transactions face heightened scrutiny. Section 588FDA of the Corporations Act gives liquidators a specific tool to recover them—with a four-year look-back period and a broad net.
Director who received payments before your company’s collapse?
Book a confidential strategy call
What Is s588FDA?
Section 588FDA was introduced by the Corporations Legislation Amendment (Insolvency) Act 2010 (Cth) to fill a gap in the voidable transaction regime. It allows a liquidator to recover transactions between the company and its directors (or their close associates) that would not have been approved by a disinterested board of directors applying reasonable commercial judgment.
Who Are ‘Director-Related Entities’?
Section 588FDA applies to transactions between the company and:
- A director of the company at the time of the transaction
- A close associate of a director—including their spouse, children, parents, or other relatives
- A company in which a director or close associate has a relevant interest
The definition is deliberately broad to capture transactions that are structured to route value to people connected with directors without going through them directly.
The Test: s588FDA(1)
A transaction is an unreasonable director-related transaction if a reasonable person in the company’s circumstances would not have entered into it. In applying this test, the court considers:
- The benefit (if any) to the company
- The detriment to the company
- The respective benefits to the directors or associates
- Any other relevant matter
Unlike unfair preferences, insolvency is not a required element of s588FDA. The transaction can be challenged even if the company was solvent at the time, provided it occurred within the four-year look-back period.
The Look-Back Period
Section 588FE(6A) provides a four-year look-back period for s588FDA transactions. This is longer than the general two-year period for uncommercial transactions and the six-month period for preferences—reflecting the heightened concern about director self-dealing.
Common Examples
Transactions commonly challenged under s588FDA include:
- Director salary increases, bonuses, or loans in the period before insolvency
- Transfer of company assets to a director or their family at undervalue
- Payments to related entities for services with no or limited commercial benefit
- Repayment of director loans in preference to external creditors
- Grant of securities or guarantees in favor of director-related parties
Defenses
Unlike unfair preferences, the s588FG good faith defence does not apply to s588FDA claims. A director cannot rely on their own good faith. The primary defense is to establish that the transaction was, in fact, reasonable—that a disinterested board would have approved it on the terms given. Evidence of independent approval, market-rate transactions, and commercial justification are critical.
Frequently Asked Questions
Q: Does the company have to be insolvent when the transaction occurred?
A: No—this is a key difference from insolvent trading and preference claims. S588FDA does not require insolvency at the time of the transaction. The four-year look-back period means transactions made well before the collapse can be challenged.
Q: Can a director loan repayment be caught?
A: Yes. Repayment of a director’s loan before insolvency can be an unreasonable director-related transaction if a disinterested board would not have approved repayment at that time—particularly where external creditors were being left unpaid.
Q: Is a director’s salary caught by S588FDA?
A: Ordinary salary paid at market rates is unlikely to be caught. Extraordinary salary increases, retrospective bonuses, or payments that deviate significantly from market rates face scrutiny—particularly where the company was deteriorating financially.
Q: What evidence does the liquidator use?
A: Liquidators review the company’s books, financial records, board resolutions (or absence thereof), and correspondence to identify director-related payments. They often instruct forensic accountants to reconstruct the transaction history.
Q: Can the good faith defense from S588FG apply?
A: Section 588FG does not apply to s588FDA transactions. This is intentional—directors cannot rely on their own good faith where they are the beneficiary of the transaction. The only real defense is that the transaction was objectively reasonable.
Q: What if the payment was made to a director’s company rather than the director personally?
A: Section 588FDA extends to related entities. A payment to a company associated with a director is within the regime. Liquidators trace the substance of the transaction, not just its form.